Sign In

Andrey Mladentsev

ALVANSA

Andrey Mladentsev (拇拉坚采夫) is a healthcare professional who has held several leadership positions in the pharmaceutical industry.13 He served as the CEO of Promomed Group from June 2020 to April 2021.1 Prior to his role at Promomed, Mladentsev was the General Manager of OBL Pharm from August 2011 to February 2020.1 His experience also includes serving as the VP for CIS & Baltics at Stada and CEO at NizhPharm, which was later acquired by Stada.3

During his tenure as CEO of Promomed, Mladentsev oversaw significant developments in the company, including the launch of Areplivir, a drug recommended by the Russian Ministry of Health for COVID-19 treatment.2 He also stated that the company would continue to focus on realizing scientific and innovative potential when Promomed DM LLC issued its first bonds on the Moscow stock exchange in 2021.4

Mladentsev's leadership coincided with Promomed's growth as a leading innovative biopharmaceutical company in Russia, with a diverse portfolio of medicines and a strong presence in various therapeutic areas.25

Highlights

Jan 1 · promomed.ru
PROMOMED - Промомед
Nov 29 · en.wikipedia.org
Promomed
Mar 4 · promomed.ru
PROMOMED DM LLC exchange bonds are now on the stock market ...
Feb 6 · promomed.ru
Promomed

Related Questions

What are Andrey Mladentsev's main achievements at PromoMed?
How did Andrey Mladentsev transition from OBL Pharm to PromoMed?
What is the significance of the Biokhimik plant in PromoMed's operations?
How has PromoMed's ranking in the obesity treatment segment impacted its growth?
What innovative medicines has PromoMed developed under Andrey Mladentsev's leadership?
Andrey Mladentsev
Andrey Mladentsev, photo 1
Andrey Mladentsev, photo 2
Add to my network

Location

Moscow, Moscow, Russia